---
reference_id: "PMID:39806603"
title: "A phase II double-blind multicentre, placebo-controlled trial to assess the efficacy and safety of alpelisib (BYL719) in paediatric and adult patients with Megalencephaly-CApillary malformation Polymicrogyria syndrome (MCAP): the SESAM study protocol."
authors:
- Luu M
- Vabres P
- Espitalier A
- Maurer A
- Garde A
- Racine C
- Carpentier M
- Rega A
- Loffroy R
- Hadouiri N
- Boddaert N
- Curie A
- Guibaud L
- Chebbi M
- Charligny J
- Kuentz P
- Canaud G
- Bahi-Buisson N
- Fleck C
- Cransac A
- Bardou M
- Faivre L
- SESAM study group
journal: BMJ Open
year: '2024'
doi: 10.1136/bmjopen-2024-084614
content_type: abstract_only
---

# A phase II double-blind multicentre, placebo-controlled trial to assess the efficacy and safety of alpelisib (BYL719) in paediatric and adult patients with Megalencephaly-CApillary malformation Polymicrogyria syndrome (MCAP): the SESAM study protocol.
**Authors:** Luu M, Vabres P, Espitalier A, Maurer A, Garde A, Racine C, Carpentier M, Rega A, Loffroy R, Hadouiri N, Boddaert N, Curie A, Guibaud L, Chebbi M, Charligny J, Kuentz P, Canaud G, Bahi-Buisson N, Fleck C, Cransac A, Bardou M, Faivre L, SESAM study group
**Journal:** BMJ Open (2024)
**DOI:** [10.1136/bmjopen-2024-084614](https://doi.org/10.1136/bmjopen-2024-084614)

## Content

1. BMJ Open. 2024 Dec 20;14(12):e084614. doi: 10.1136/bmjopen-2024-084614.

A phase II double-blind multicentre, placebo-controlled trial to assess the 
efficacy and safety of alpelisib (BYL719) in paediatric and adult patients with 
Megalencephaly-CApillary malformation Polymicrogyria syndrome (MCAP): the SESAM 
study protocol.

Luu M(1)(2), Vabres P(3)(4), Espitalier A(5), Maurer A(5), Garde A(2)(5), Racine 
C(2)(5), Carpentier M(6), Rega A(7), Loffroy R(7), Hadouiri N(8), Boddaert 
N(9)(10), Curie A(11), Guibaud L(12), Chebbi M(13), Charligny J(14), Kuentz 
P(2)(15), Canaud G(9)(16), Bahi-Buisson N(10)(17), Fleck C(6), Cransac 
A(18)(19), Bardou M(14)(2), Faivre L(2)(5); SESAM study group.

Collaborators: Demeer B, Colin E, Boucher-Brischoux E, Brosseau-Beauvir A, 
Francannet C, Cherik F, Treluyer JM, Petit F, Phan A, Semeraro M, Nys M, Roux 
CJ, Kien PKV, Lavillaureix A, Maruani I.

Author information:
(1)Centre d'investigation clinique - module plurithématique (CIC-P) INSERM 1432, 
Centre Hospitalier Universitaire de Dijon, Dijon, Bourgogne-Franche-Comté, 
France Maxime.luu@chu-dijon.fr.
(2)INSERM UMR1231 Génétique des Anomalies du Développement (GAD), Université de 
Bourgogne, Dijon, France.
(3)Dermatology, Centre référence MAGEC, Dijon, France.
(4)St John's Institute of Dermatology, London, UK.
(5)Centre de Référence Anomalies du Développement et Syndromes Malformatifs et 
FHU TRANSLAD, Centre Hospitalier Universitaire de Dijon, Dijon, 
Bourgogne-Franche-Comté, France.
(6)Direction de la Recherche Clinique, Centre Hospitalier Universitaire de 
Dijon, Dijon, Bourgogne-Franche-Comté, France.
(7)Département de Radiologie et Imagerie Diagnostique et Thérapeutique, Centre 
Hospitalier Universitaire de Dijon, Dijon, Bourgogne-Franche-Comté, France.
(8)Département de Médecine Physique et de Réadaptation, Centre Hospitalier 
Universitaire de Dijon, Dijon, Bourgogne-Franche-Comté, France.
(9)INSERM UMR-1163 Institut Imagine, Hôpital Universitaire Necker-Enfants 
Malades, Paris, France.
(10)Département de Radiologie Pédiatrique, Hôpital Necker-Enfants Malades, 
Assistance Publique - Hopitaux de Paris, Paris, Île-de-France, France.
(11)Centre de référence Déficience Intellectuelle de causes rares, Service de 
neuropédiatrie, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Lyon, 
Auvergne-Rhône-Alpes, France.
(12)Service d'Imagerie Pédiatrique, Hôpital Femme-Mère-Enfant, Hospices Civils 
de Lyon, Lyon, Auvergne-Rhône-Alpes, France.
(13)Service de Pharmacologie périnatale, pédiatrique et adulte (site HEGP), 
Recherche Clinique Entrepôts de Données et Pharmacologie, GHU Paris. Université 
Paris Cité, Assistance Publique - Hopitaux de Paris, Paris, Île-de-France, 
France.
(14)Centre d'investigation clinique - module plurithématique (CIC-P) INSERM 
1432, Centre Hospitalier Universitaire de Dijon, Dijon, Bourgogne-Franche-Comté, 
France.
(15)Oncobiologie Génétique Bioinformatique, FHU-TRANSLAD et Institut GIMI, 
Centre Hospitalier Universitaire de Besancon, Besancon, Bourgogne-Franche-Comté, 
France.
(16)INSERM U1151, Unité de médecine translationnelle et thérapies ciblées, 
Hôpital Necker-Enfants Malades, Université Paris Cité, Paris, Île-de-France, 
France.
(17)Service de Neurologie Pédiatrique, DMU MICADO, Hôpital Necker Enfants 
Malades, Assistance Publique - Hopitaux de Paris, Paris, Île-de-France, France.
(18)Département de Pharmacie, Centre Hospitalier Universitaire Dijon Bourgogne, 
Dijon, Bourgogne-Franche-Comté, France.
(19)INSERM LNC-UMR1231, Université de Bourgogne, Dijon, Bourgogne-Franche-Comté, 
France.

INTRODUCTION: The megalencephaly capillary malformation polymicrogyria (MCAP 
syndrome) results from mosaic gain-of-function PIK3CA variants. The main 
clinical features are macrocephaly, somatic overgrowth, neurodevelopmental delay 
and brain anomalies. Alpelisib (Vijoice) is a recently FDA-approved 
PI3Kα-specific inhibitor for patients with PIK3CA-related overgrowth spectrum 
(PROS). During its development, in patients with the MCAP subgroup of PROS, 
there was no specific, standardised evaluation of the effect on neuro-cognitive 
functioning. Moreover, it remains unknown if the molecule crosses the 
blood-brain barrier. Our objective is to evaluate the efficacy of a 24 month 
treatment with alpelisib on adaptive behaviour in patients with MCAP syndrome.
METHODS AND ANALYSIS: SESAM is an industry-sponsored two-period multicentre 
French academic phase II trial, with a 6-month double-blind, placebo-controlled 
period followed by an open-label period. The primary endpoint is a ≥4-point 
improvement in the Vineland II Adaptive Behaviour Scale (VABS), 24 months after 
treatment initiation. Secondary objectives are safety, VABS improvement at 6 
months, impact on the quality of life, epilepsy and hypotonia. 20 patients aged 
2 to 40 years with an MCAP diagnosis and neurodevelopmental disorders of various 
degrees, will be followed monthly in local centres, centrally assessed 
(clinical, biological, neuropsychological and functional evaluation) at baseline 
and every 6 months. Patients will be evaluated by volumetric MRI at baseline and 
at 24 months. An optional lumbar puncture will be performed to investigate 
blood-brain barrier crossing. Inclusions were completed by April 2024, with the 
end of follow-up in November 2026.Given the efficacy of alpelisib in patients 
with PROS, if the drug crosses the blood-brain barrier, we can expect a clinical 
benefit for patients with neurocognitive disorders.
ETHICS AND DISSEMINATION: Ethical approval was given by CPP Sud-Ouest et 
Outre-Mer I (reference: 2022-500197-34-01). Findings from this study will be 
disseminated via publication, reports and conference presentations.
TRIAL REGISTRATION NUMBER: NCT05577754.

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No 
commercial re-use. See rights and permissions. Published by BMJ Group.

DOI: 10.1136/bmjopen-2024-084614
PMCID: PMC11667470
PMID: 39806603 [Indexed for MEDLINE]

Conflict of interest statement: Competing interests: A patent application 
('BYL719 (alpelisib) for the use in the treatment of PIK3CA-related overgrowth 
spectrum' #WO2017140828A1) has been filed by INSERM (Institut National de la 
Santé et de la Recherche Médicale), Centre National De La Recherche Scientifique 
(CNRS), Université Paris Cité and Assistance Publique-Hôpitaux De Paris (AP-HP) 
for the use of BYL719 (alpelisib) in the treatment of PIK3CA-related overgrowth 
spectrum (PROS/CLOVES syndrome). Dr Canaud is the inventor. This patent is 
licensed to Novartis Pharmaceutical. ML has received consulting fees from 
Novartis Pharmaceutical. GC receives or has received consulting fees from 
Novartis Pharmaceutical, Fresenius Medical Care, Vaderis, Alkermes, IPSEN and 
BridgeBio.